Inhibition of the malate-aspartate shuttle by pre-ischaemic aminooxyacetate loading of the heart induces cardioprotection

Cardiovasc Res. 2010 Nov 1;88(2):257-66. doi: 10.1093/cvr/cvq205. Epub 2010 Jun 18.

Abstract

Aims: Preserved mitochondrial function is essential for protection against ischaemia-reperfusion (IR) injury. The malate-aspartate (MA) shuttle constitutes the principal pathway for transport of reducing cytosolic equivalents for mitochondrial oxidation. We hypothesized that a transient shut-down of the MA-shuttle by aminooxyacetate (AOA) during ischaemia and early reperfusion modulates IR injury by mechanisms comparable to ischaemic preconditioning (IPC).

Methods and results: Isolated perfused rat hearts exposed to 40 min global no-flow ischaemia were studied in: (i) control, (ii) pre-ischaemic AOA (0.1 mM), (iii) IPC, and (iv) AOA+IPC hearts. IR injury was evaluated by infarct size and haemodynamic recovery. Tracer-estimated glucose oxidation and metabolic changes in glycogen, lactate, pyruvate, tricarboxylic acid (TCA) cycle intermediates, and ATP degradation products were measured. The effects of AOA on complex I respiration and reactive oxygen species (ROS) production were examined in isolated rabbit mitochondria. Treatment with AOA, IPC, or AOA+IPC induced significant infarct reduction; 28 ± 6, 30 ± 3, and 18 ± 1%, respectively, vs. 52 ± 5% of left ventricular (LV) mass for control (P < 0.01 for all). LV-developed pressure improved to 60 ± 3, 63 ± 5 and 53 ± 4 vs. 31 ± 5 mmHg (P < 0.01 for all) after 2 h reperfusion. Pre-ischaemic AOA administration inhibited glycolysis and increased glucose oxidation during post-ischaemic reperfusion similar to IPC, and suppressed complex I respiration and ROS production in the non-ischaemic heart. Changes in lactate, pyruvate, TCA intermediates, and ATP end products suggested an AOA inhibition of the MA-shuttle during late ischaemia and early reperfusion.

Conclusion: Inhibition of the MA-shuttle during ischaemia and early reperfusion is proposed as a mechanism to reduce IR injury.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminooxyacetic Acid / pharmacology*
  • Animals
  • Aspartic Acid / metabolism*
  • Cardiotonic Agents / pharmacology*
  • Cell Respiration / drug effects
  • Energy Metabolism / drug effects*
  • Glucose / metabolism
  • Hemodynamics / drug effects
  • In Vitro Techniques
  • Ischemic Preconditioning, Myocardial*
  • Malates / metabolism*
  • Male
  • Microdialysis
  • Mitochondria, Heart / drug effects*
  • Mitochondria, Heart / metabolism
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / pathology
  • Myocardial Infarction / prevention & control
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / pathology
  • Myocardial Reperfusion Injury / physiopathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Oxidation-Reduction
  • Oxygen Consumption / drug effects
  • Perfusion
  • Rabbits
  • Rats
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism
  • Time Factors
  • Ventricular Function, Left / drug effects
  • Ventricular Pressure / drug effects

Substances

  • Cardiotonic Agents
  • Malates
  • Reactive Oxygen Species
  • Aminooxyacetic Acid
  • Aspartic Acid
  • malic acid
  • Glucose